Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2395 - Dynamic monitoring of KRAS, NRAS, BRAF and PIK3CA mutations in circulating cell-free DNA for metastatic colorectal cancer patients treated with cetuximab

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Lu Liu

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

L.L. Liu, Z. Tong, C. Yan, H. Zhang, W. Jiang, Y. Zheng, P. Zhao, W. Fang

Author affiliations

  • Medical Oncology, 1st Affiliated Hospital of Zhejiang University School of Medicine, 310003 - Hangzhou/CN
More

Resources

Abstract 2395

Background

Genomic heterogeneity affects response to targeted agents. Liquid biopsy is a promising approach to detect genetic mutations in circulating cellfree DNA (cfDNA) and allows the tracking of treatment-induced genetic evolution in metastatic colorectal cancer (mCRC) patients.

Methods

Longitudinal plasma samples (n = 92) were collected from 15 mCRC patients receiving cetuximab contained regimen therapy. KRAS, NRAS, BRAF and PIK3CA mutational status relevant to cetuximab resistance were monitored by next-generation sequencing in plasma, which could be reflected by variant allele frequency (VAF). We also included 11 healthy controls to differentiate total cfDNA levels from mCRC patients.

Results

Of these 15 mCRC patients, baseline plasmas were collected in 8 patients. The average cfDNA level in treatment naive patients was significantly higher than healthy cohort (p = 0.0004). Moreover, cfDNA levels correlate with the tumor burden before systemic therapy (R2=0.544). Dynamics of KRAS/NRAS/BRAF/PIK3CA VAF mirrored disease evolution, showing the same trend with partial response, disease progression and relapse. In addition, KRAS/NRAS/BRAF/PIK3CA VAF gradually declined upon cetuximab withdrawal for more than 2 months, and partial response was again achieved when cetuximab was re-used on 1 patient. This provided a molecular explanation for the efficacy of rechallenge therapies based on EGFR blockade.

Conclusions

Dynamic monitoring of KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA is feasible and appears to be useful in early detection of drug resistance to cetuximab in mCRC patients.

Clinical trial identification

Legal entity responsible for the study

Weijia Fang.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.